8-K: ZimVie Agrees to $730 Million Cash Acquisition by ARCHIMED, Offering 99% Premium to Shareholders

ZimVie Inc., a global life sciences leader in the dental implant market, has entered into a definitive agreement to be acquired by an affiliate of ARCHIMED for $19.00 per share in cash, representing a significant premium for its stockholders.

Summary

• ZimVie Inc. has signed a definitive Agreement and Plan of Merger with Zamboni Parent Inc. and Zamboni MergerCo Inc., an affiliate of ARCHIMED.
• Under the agreement, ZimVie stockholders will receive $19.00 in cash for each share of common stock.
• The total enterprise value of the transaction is approximately $730 million.
• The per-share price of $19.00 represents a 99% premium to ZimVie's 90-day volume-weighted average price (VWAP) of $9.57 per share.
• The transaction has been unanimously approved by ZimVie's Board of Directors.
• Consummation of the merger is subject to customary closing conditions, including approval by ZimVie's stockholders and applicable regulatory approvals (e.g., Hart-Scott-Rodino Antitrust Improvements Act of 1976, non-U.S. antitrust, and foreign direct investment approvals).
• The transaction is not subject to a financing condition, with Parent having secured equity and debt financing commitments.
• A 'Go-Shop Period' is in effect until August 29, 2025, allowing ZimVie to solicit alternative acquisition proposals, with a potential extension until September 3, 2025, for 'Excluded Parties'.
• Upon closing, ZimVie will become a privately held company, and its shares will be delisted from the NASDAQ stock exchange.
• Equity awards (RSUs, Options, DSUs) will vest in full and be converted into cash payments based on the $19.00 merger consideration, with options having an exercise price equal to or greater than the merger consideration being canceled for no consideration.
• The Company will pay a termination fee of $20,251,575 to Parent under specified circumstances, or $10,125,785 if terminated for a Superior Proposal from an Excluded Party during the Go-Shop Period or Extension.
• Parent will pay a termination fee of $40,503,150 to the Company if Parent fails to consummate the merger when required.

Sentiment

Score: 9

Explanation: The sentiment is highly positive due to the substantial 99% premium offered to shareholders, the unanimous board approval, and the deal not being subject to a financing condition, indicating high certainty of closing at a favorable price.

Positives

• The acquisition price of $19.00 per share represents a substantial 99% premium over ZimVie's 90-day volume-weighted average price of $9.57, providing significant immediate value to shareholders.
• The transaction is not subject to a financing condition, indicating a high degree of certainty regarding the availability of funds for the acquisition.
• The unanimous approval by ZimVie's Board of Directors suggests strong internal support for the deal.
• Partnering with ARCHIMED, an investment firm exclusively focused on healthcare, is expected to provide strategic and financial backing to expand ZimVie's innovative dental technology globally.

Negatives

• Upon completion, ZimVie will become a privately held company, and its shares will no longer be listed on NASDAQ, removing public trading opportunities for current shareholders.
• The 'Go-Shop Period' and potential for a 'Superior Proposal' introduce a degree of uncertainty, though the company's board has already unanimously approved the current deal.
• The company will incur a termination fee of $20,251,575 (or $10,125,785 in specific cases) if the agreement is terminated under certain circumstances, such as for a superior proposal or if the company breaches the agreement.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Failure to receive required approvals from ZimVie's stockholders could prevent the merger.
• Various closing conditions, including regulatory approvals from governmental entities (U.S. and non-U.S. antitrust, foreign direct investment), may not be satisfied or could have conditions/limitations placed on them.
• Competing offers or acquisition proposals for ZimVie could emerge.
• The occurrence of any event or change that could lead to the termination of the definitive transaction agreement, potentially requiring ZimVie to pay a termination fee.
• The announcement or pendency of the proposed transaction may negatively impact ZimVie's ability to attract, motivate, or retain key executives and employees.
• The transaction could affect ZimVie's ability to maintain relationships with its customers, suppliers, and other business counterparties, or its operating results and business generally.
• The proposed transaction may divert management's attention from ZimVie's ongoing business operations.
• There is a risk of stockholder litigation in connection with the proposed transaction, which could result in expense or delay.

Future Outlook

The transaction is expected to close by year-end 2025, subject to stockholder and regulatory approvals. Upon completion, ZimVie will transition to a privately held company, aiming to expand its innovative dental technology globally with strategic and financial backing from ARCHIMED.

Management Comments

• "This transaction marks a new chapter for ZimVie and underscores the value our team has built over the past several years." Vafa Jamali, Chairman of the Board and Chief Executive Officer of ZimVie.
• "Partnering with ARCHIMED will create value for our shareholders while providing the strategic and financial backing to expand our innovative dental technology to more patients globally." Vafa Jamali, Chairman of the Board and Chief Executive Officer of ZimVie.
• "We're excited to partner with ZimVie and its talented team. The company has strong fundamentals and compelling growth potential, and we look forward to supporting its next chapter." Andr-Michel Ballester, Managing Partner, at ARCHIMED.

Industry Context

This acquisition highlights continued consolidation and private equity interest in the life sciences and medical technology sectors, particularly in specialized markets like dental implants. ARCHIMED's exclusive focus on healthcare industries suggests a strategic move to leverage ZimVie's position as a global leader in dental tooth replacement and restoration, potentially indicating a belief in the long-term growth and innovation potential within this niche. The move to private ownership could allow ZimVie to pursue long-term strategic initiatives without the pressures of quarterly public reporting.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• Risk of stockholder litigation in connection with the proposed transaction, including resulting expense or delay.

Related Party Transactions

• The equity financing commitment is from Med Platform II S.L.P., an affiliate of Parent (ARCHIMED), which is a related party transaction.

Stakeholder Impact

• **Shareholders**: Will receive a significant cash premium ($19.00 per share), representing a 99% premium to the 90-day VWAP, providing immediate and substantial value. Shares will be delisted, ending public trading.
• **Employees**: The announcement may affect the company's ability to attract, motivate, or retain key executives and employees due to the change in ownership. Management's attention may be diverted from ongoing business operations.
• **Customers, Suppliers, and Business Counterparties**: The announcement and pendency of the transaction could impact existing relationships, though the company is operating business as usual.
• **Management**: Equity awards will vest in full and convert to cash, providing a liquidity event. Management's attention may be diverted by the transaction process.

Next Steps

• ZimVie will operate business as usual until the deal's closing.
• ZimVie will solicit alternative acquisition proposals during a 40-day 'Go-Shop Period' ending August 29, 2025, with a potential 5-day extension for 'Excluded Parties'.
• ZimVie stockholders must approve the transaction.
• Applicable regulatory approvals (e.g., HSR Act, non-U.S. antitrust, foreign direct investment) must be obtained.
• The transaction is expected to close by year-end 2025.
• Upon completion, ZimVie shares will be delisted from NASDAQ and the company will become privately held.

Key Dates

Recommendation

Keywords

ZimVie Inc., ARCHIMED, Merger Agreement, Acquisition, Dental Implant Market, Cash Transaction, Stockholder Approval, Regulatory Approvals, Go-Shop Period, Delisting, SEC Filing, 8-K, Healthcare Industry, Private Equity